Ardelyx Inc.
34175 Ardenwood Boulevard
Suite 100
Fremont
California
94555
United States
Tel: 510-745-1700
Website: http://www.ardelyx.com/
253 articles about Ardelyx Inc.
-
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
10/20/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced three posters will be presented at the American Society of Nephrology (ASN) Kidney Week 2022 to be held November 3-6, 2022, in Orlando, Florida.
-
Ardelyx, Inc. Reports Employment Inducement Grants - September 30, 2022
9/30/2022
Ardelyx, Inc. announced that on September 26, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 56,250 shares of the company's common stock, and an aggregate of 26,000 Restricted Stock Units.
-
Ardelyx to Participate in Upcoming September 2022 Investor Conferences
9/6/2022
Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, announced its participation in the following upcoming investor conferences:
-
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/4/2022
Ardelyx, Inc. (Nasdaq: ARDX), today reported business updates and financial results for the second quarter ended June 30, 2022.
-
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
Ardelyx, Inc. today announced that Mike Raab , president and chief executive officer of Ardelyx, will participate in a virtual fireside chat at the 2022 Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Tuesday, August 9, 2022, at 4:40 p.m. ET.
-
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
Ardelyx, Inc. today announced that it will hold a conference call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time to review second quarter 2022 financial results and provide a business overview.
-
Ardelyx, Inc. Reports Employment Inducement Grants - July 01, 2022
7/1/2022
Ardelyx, Inc. announced that on June 28, 2022, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company's common stock, and granted an aggregate of 83,375 Restricted Stock Units to eight new non-executive employees.
-
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
6/30/2022
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from Ardelyx Japanese collaboration partner.
-
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
6/21/2022
Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022.
-
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
6/3/2022
Ardelyx, Inc. will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022, at 8:30 a.m. ET in New York City.
-
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
5/24/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that new analyses from IBSRELA Phase 3 trials, T3MPO-1 and T3MPO-2, were presented in three poster presentations at the 2022 Digestive Disease Week Conference.
-
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
5/17/2022
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in three posters at the 2022 Digestive Disease Week Conference.
-
Ardelyx, Inc. Reports Employment Inducement Grants - May 16, 2022
5/16/2022
Ardelyx, Inc. announced that on May 9, 2022, the compensation committee of the company's board of directors granted three new non-executive employees options to purchase an aggregate of 26,953 shares of the company's common stock, and granted an aggregate of 29,250 Restricted Stock Units to six new non-executive employees.
-
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/5/2022
Ardelyx, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2022.
-
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
4/28/2022
Ardelyx, Inc. today announced that it will hold a conference call on Thursday May 5 at 4:30 pm Eastern Time to review first quarter 2022 financial results and provide a business overview.
-
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
4/25/2022
Ardelyx, Inc. today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA), has provided an interim response to Ardelyx's second level of appeal of the Complete Response Letter (CRL) received on July 28, 2021, for XPHOZAH.
-
Ardelyx announced the FDA's OND, CDER, provided an interim response to the company's second level of appeal for tenapanor. Here's what you need to know.
-
Ardelyx, Inc. Reports Employment Inducement Grants - Apr 12, 2022
4/12/2022
Ardelyx, Inc. announced that on April 5, 2022, the compensation committee of the company's board of directors granted five new non-executive employees options to purchase an aggregate of 68,797 shares of the company's common stock, and an aggregate of 33,450 Restricted Stock Units.
-
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
4/11/2022
Ardelyx, Inc. today announced that it has reached an agreement with its Japanese collaboration partner, Kyowa Kirin Co. Ltd., to amend the license agreement, originally executed in 2017, that grants to Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.
-
The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here's a look at the latest.